Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, ...

Eli Lilly (NYSE:LLY) reported positive topline Phase 3 results for EBGLYSS (lebrikizumab) in pediatric patients with moderate ...

HealthDay News — For children aged 2 to 5 years with atopic dermatitis (AD), roflumilast cream 0.05% has a favorable long-term safety profile and efficacy for up to 56 weeks, according to a study ...

Spanish dermatology specialist Almirall has announced positive, top-line results from the pivotal Phase III ADorable-1 trial ...

On Friday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s NVS Cosentyx (secukinumab) for younger patients. The approval covers pediatric patients 12 years and older with moderate ...

Pediatric patients with moderate to severe hidradenitits suppurativa may now receive secukinumab following new FDA approval for those aged 12 and up.

The FDA approved secukimumab for children aged 12 years and older with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.The approval makes secukinumab (Cosentyx) the ...

Dermatologists remain concentrated in well-resourced, metropolitan communities, and persistent maldistribution is associated ...

Regulatory clearance positions secukinumab as the sole IL‑17A–targeting option for pediatric HS, expanding therapeutic choice beyond historically limited adolescent interventions. IL‑17A blockade is ...

CMO, director of clinical research at Frontier Dermatology in Mill Creek, Washington, spoke about updates in the pediatric psoriasis space presented at Maui Derm 2026.

Beijing is launching pilot initiatives to support childbearing and childcare as part of efforts to establish a ...